



Endocrine Disorders: From Pathophysiology to Novel Therapeutic Approaches

Guest Editor:

Dr. Esther Osher

Institute of Endocrinology,
Metabolism, and Hypertension,
Tel Aviv-Sourasky Medical Center,
Sackler Faculty of Medicine, Tel
Aviv University, Israel

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Dear Colleagues,

Endocrine disorders result from dysfunction of the endocrine system. The endocrine system includes the glands that secrete hormones, the receptors that respond to hormones, and the organs directly affected by hormones. Dysfunction may occur at any point and affect the body's metabolic process, growth and development, reproductive aging, and many other physiological activities. Endocrine disorders are complex chronic diseases. More and more people are suffering from them. However, the current therapeutic options and effects are all limited and often accompanied by adverse reactions.

This Special Issue will cover all research on the molecular mechanisms of the pathophysiology of all endocrine disorders, cellular and animal disease models, new drugs, and cell and gene therapy options.

Dr. Esther Osher

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)